Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)

NCT06794125 is registered in ClinicalTrials.gov with Chris Goodman as lead sponsor.

NCT NCT06794125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)
Lead sponsor
Chris Goodman
Phase
Not applicable
Overall status
Recruiting
Start date
September 3, 2025
Completion date
March 1, 2029
Enrollment
141 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancers